Related Experiment Videos

[Anti-pneumococcal immunity in extra-hospital acute pneumonia in children]

L A Vishniakova1, T S Sologub, S L Akimova

  • 1State Research Centre of Pulmonology, St. Petersburg, Russia.

Zhurnal Mikrobiologii, Epidemiologii I Immunobiologii
|November 24, 1998
PubMed

Insights

In children with acute pneumonia, all patients had Streptococcus pneumoniae antibodies, with immunity developing early. Antibiotic therapy suppressed antibody formation, especially in young children.

Area of Science:

  • Pediatrics
  • Immunology
  • Infectious Diseases

Background:

  • Streptococcus pneumoniae is a common cause of childhood pneumonia.
  • Understanding the immune response to Streptococcus pneumoniae is crucial for effective treatment and prevention strategies.

Purpose of the Study:

  • To investigate the humoral immune response to Streptococcus pneumoniae in children with acute pneumonia.
  • To assess the impact of age, disease duration, and antibiotic therapy on antipneumococcal antibody levels.

Main Methods:

  • Pulmonological examination of 134 children aged 1 month to 14 years.
  • Indirect immunofluorescence test to detect antibodies to Streptococcus pneumoniae.
  • Analysis of antibody levels in relation to disease stage, age, and treatment.

Main Results:

  • All patients exhibited antibodies to Streptococcus pneumoniae, indicating local humoral immunity dominance.
  • Antipneumococcal antibody formation was rapid, occurring within the first week of illness.
  • Children under 3 years showed less stable immunity, though some had high antibody levels.
  • Early antibiotic therapy significantly suppressed antipneumococcal antibody development.
  • Concomitant viral or mycoplasmic infections did not affect antipneumococcal antibody synthesis.

Conclusions:

  • Children with acute pneumonia mount an early and robust humoral immune response to Streptococcus pneumoniae.
  • Younger children (under 3 years) may have a less stable antipneumococcal immune response.
  • Antibiotic therapy can interfere with the development of protective antipneumococcal immunity.
  • Further research is needed to optimize treatment strategies balancing infection control and immune response.

Related Concept Videos